Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Selective hydrogenation process employing a catalyst having a controlled porosity
申请人:Institut Francais du Petrole
公开号:US07718053B2
公开(公告)日:2010-05-18
A process for jointly carrying out selective hydrogenation of polyunsaturated compounds into monounsaturated compounds contained in gasolines, and for transforming light sulphur-containing compounds into heavier compounds by reaction with unsaturated compounds employing a supported catalyst, comprising at least one metal from group VIB and at least one non-noble metal from group VIII used in the sulphurized form deposited on a support and having a controlled porosity, and comprising bringing the feed into contact with the catalyst at a temperature in the range of 80° C. to 220° C. at a liquid hourly space velocity in the range of 1 h−1 to 10 h−1 and at a pressure in the range of 0.5 to 5 MPa.